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Abstract: During early stage of pre-clinical biologics development, grams of 
product antibody is needed for process development, formulation 
development, and analytical assay development. To accelerate the pre-
clinical timeline, it's a common practice to use master wells (non-clonal 
stable cell pools) to generate development material.  The advantage of 
using master wells is that the product antibody is generated from the same 
host cell line and expression vector in an earlier and shorter time. Thus, the 
purified product antibody can be representative to the final therapeutic 
product.  However, the non-clonal nature of the cell pools can give rise to 
potential risk of heterogeneity in product quality exhibited in charge 
variants, glycan profile, etc. Herein, we present a case study on the 
evaluation of charge variant heterogeneity, its root cause, and impact. The 
increase fraction of acidic variants was first discovered in the in-process 
analytics by isoelectric focusing (iCIEF). Tryptic peptide mapping LC-MS 
analysis of purified drug substance further indicated an exchange of Lysine 
to Asparagine in the Fc region. Subsequent cDNA analysis of the single-cell 
clones from a master well that produced the purified product revealed a 
single substitution mutation that results in the amino acid substitution. 
Although the material used for development was a mixture of antibody 
product, process development, formulation development, and analytical 
development were not impacted. The risk of using mutated, potential non-
representative variant was further mitigated by bridging studies, confirming 
product produced by single-cell clones. This case is a demonstration of a 
worst case scenario, in which a larger percentage (about 40%) 
heterogeneity was introduced via a point mutation at the DNA level. 
Nevertheless, overall time line for this program was not affected; thus the 
time saving benefits of this strategy outweigh the disadvantages and 
supports the use of non-clonal cell pool in the fast paced early stage 
development space.  
